Pharmacokinetics of methotrexate–albumin conjugates in tumor-bearing rats

@article{Stehle1997PharmacokineticsOM,
  title={Pharmacokinetics of methotrexate–albumin conjugates in tumor-bearing rats},
  author={Gerd Stehle and Andreas Wunder and Hannsjörg Sinn and Hans Hermann Schrenk and Sandra Schiitt and Eva Frei and Gernot Hartung and W Maier-borst and Dieter L. Heene},
  journal={Anti-Cancer Drugs},
  year={1997},
  volume={8},
  pages={835-844}
}
Linking chemotherapeutic drugs to a macromolecular carrier system may enhance tumor targeting, reduce toxicity and overcome drug resistance mechanisms. As an elementary model to evaluate the pharmacological properties of macromolecular drug carrier systems we chose rat serum albumin (RSA) for carrier and methotrexate (MTX) as antineoplastic drug. The conjugation procedure yielded conjugates with an approximate 1:1 molar loading rate (MTX(1)-RSA). In the first part of the study a residualizing… 

Antitumor activity of methotrexate‐albumin conjugates in rats bearing a Walker‐256 carcinoma

MTX‐albumin conjugates show therapeutic activity in vivo without toxic side effects and are evaluated for the combination treatment with MTX and MTX‐ albumin, with complete remission in all 20 rats.

Efficacy and tolerability of an aminopterin–albumin conjugate in tumor-bearing rats

In this comparative study, the AMPT–SA conjugate showed high antitumor activity in vivo and a favorable toxicity compared to low-molecular-weight AMPT, which seems to be an effective tool for selective tumor drug targeting.

Pre‐clinical evaluation of a methotrexate–albumin conjugate (MTX‐HSA) in human tumor xenografts in vivo

The improved therapeutic effects seen in 3 xenograft models under MTX‐HSA treatment are promising and might be due to specific accumulation of the compound in solid tumors owing to their enhanced permeability and retention effect.

ArthritisTherapeutic Approach for Rheumatoid Albumin-Based Drug Delivery as Novel

We reported recently that albumin is a suitable drug carrier for targeted delivery of methotrexate (MTX) to tumors. Due to pathophysiological conditions in neoplastic tissue, high amounts of albumin

Albumin-Based Drug Delivery as Novel Therapeutic Approach for Rheumatoid Arthritis1

We reported recently that albumin is a suitable drug carrier for targeted delivery of methotrexate (MTX) to tumors. Due to pathophysiological conditions in neoplastic tissue, high amounts of albumin

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.

  • F. Kratz
  • Biology, Chemistry
    Journal of controlled release : official journal of the Controlled Release Society
  • 2008

Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation

Albumin has shown remarkable promise as a natural drug carrier by improving pharmacokinetic (PK) profiles of anticancer drugs for tumor-targeted delivery. The exogenous or endogenous albumin enhances

Anticancer carrier-linked prodrugs in clinical trials

This review summarizes the Phase I – III studies that have been performed with drug conjugates that have recently entered clinical trials and includes a methotrexate–albumin conjugate and an albumin-binding doxorubicin prodrug.

Albumin-coupled methotrexate (MTX-HSA) is a new anti-arthritic drug which acts synergistically to MTX.

The data show that the effectiveness of MTX-HSA in CIA is superior to MTX and that both drugs act synergistically, suggesting that they might be one of the potential target cells of this novel anti-arthritic treatment approach.

Serum proteins as drug carriers of anticancer agents: a review.

This review covers the diagnostic evidence for tumor accumulation of serum proteins and the design, development, and biological evaluation of drug conjugates with transferrin, albumin, and low-density lipoprotein.
...